Our results showed that patients with cancer exhibited significantly shorter fragments of ccf-mtDNA than non-cancer controls, and ccf-mtDNA fragments with tumor-specific mutations were significantly shorter than wild-type ccf-mtDNA fragments, suggesting that tumor-derived ccf-mtDNA fragments may at least partly account for the source of aberrant fragmentomic features. This evidence concerns the gene PITX1 and neoplasm.